A Study to Evaluate the PF-06700841 Effect on QTc Interval in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 5, 2018

Primary Completion Date

February 6, 2019

Study Completion Date

February 6, 2019

Conditions

Healthy

Interventions

DRUG

PF-06700841

a single oral dose of 200 mg PF-06700841

DRUG

Placebo

Placebo matching PF-06700841

DRUG

moxifloxacin

a single oral dose of 400 mg moxifloxacin

Trial Locations (1)

Pfizer Clinical Research Unit, Brussels